Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

The other big challenge is, despite having a variety of different therapies that we can choose, a variety of different mechanisms of action, we don’t have the ability to pinpoint the right drug ...

Journal Editorial Report: Paul Gigot interviews Jason Riley about his new book. Derrick Bell is best known for his contributions to critical race theory—which claims that racism is embedded in ...

Tim McGraw fans got more good news this week as the singer plots his return to the stage after nearly a year on the mend. The 57-year-old star had to surgery on both of his knees back in August ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo was approved in 2018 for advanced cutaneous squamous cell carcinoma, and since then has also been cleared for basal cell carcinoma and most recently first-line non-small cell lung cancer ...

Interestingly, Channi, apparently alluding to the Balakot bombings, claimed that the action after Pulwama did not happen as nobody saw anything. A meeting of the CWC reiterated the demand for ...

But sometimes you don’t want that! Sometimes you just want to escape the increasingly insane world out there into an action movie. Netflix has made a few of their own, but the bulk of the best ...

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

The defects in molecular and cellular processes that constitute the triggers of specific pathologies are referred to as mechanisms of disease. Research in this area is vital for designing ...